The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Organon , a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months ...

Freshfields announced today that Phillip Stoup has joined as a capital markets partner in Silicon Valley.

An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug ...

Reports Q3 revenue $1.58B, consensus $1.56B. “In 2024 our commercial execution has been very strong. Our largest product, Nexplanon, is ...

Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. JP Morgan does not expect any major surprise in the Q3 earnings, with the generic version ...

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

The European Commission (EC) has approved AstraZeneca ‘s Fasenra (benralizumab) as an add-on therapy for adults with ...

Roivant Sciences ( (ROIV) ) has shared an update. Organon has successfully acquired Dermavant Sciences, expanding its dermatology portfolio ...

Copado, the leader in DevOps for business applications, today announced it has integrated Copado AI into its Community to streamline support and accelerate issues resolution. Recently, the Copado ...